In Jazz case, FTC urges court to delist patent on blockbuster Xyrem

In a court filing (PDF), the U.S. Federal Trade Commission (FTC) took issue with a Jazz patent that covers a system for distributing Jazz's twice-nightly narcolepsy drug Xyrem under an FDA-required program to curb treatment-related risks.